Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cellectis S.A. stock logo
CLLS
Cellectis
$1.63
+0.9%
$1.49
$1.10
$2.43
$89.49M2.91142,858 shs60,323 shs
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$3.71
+0.7%
$4.12
$2.55
$6.42
$184.01M1.0810,456 shs694 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$8.37
+3.7%
$6.11
$3.85
$8.75
$648.55M1.24397,448 shs945,554 shs
NantKwest, Inc. stock logo
NK
NantKwest
$2.79
+3.0%
$28.01
$2.52
$45.42
$305.07M2.611.57 million shs7.89 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$39.12
+5.8%
$33.36
$27.12
$60.90
$2.22B2.41966,729 shs1.08 million shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cellectis S.A. stock logo
CLLS
Cellectis
+0.93%-1.52%+14.04%+32.11%-15.14%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
+0.71%-2.60%-12.80%+13.68%-12.18%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
+3.72%+20.95%+32.44%+65.09%+107.69%
NantKwest, Inc. stock logo
NK
NantKwest
-0.37%+5.45%-13.97%+4.23%-58.31%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+5.79%+3.82%+17.27%+6.80%-22.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cellectis S.A. stock logo
CLLS
Cellectis
2.8727 of 5 stars
3.53.00.00.01.92.50.6
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
1.5002 of 5 stars
3.54.00.00.00.00.00.0
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
4.4294 of 5 stars
3.52.00.04.83.12.50.6
NantKwest, Inc. stock logo
NK
NantKwest
N/AN/AN/AN/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
4.3275 of 5 stars
4.42.00.04.42.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cellectis S.A. stock logo
CLLS
Cellectis
3.00
Buy$4.00146.15% Upside
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
3.00
Buy$13.00250.78% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$24.00186.74% Upside
NantKwest, Inc. stock logo
NK
NantKwest
0.00
N/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$50.4028.83% Upside

Current Analyst Ratings Breakdown

Latest MGTX, CLLS, TWST, NK, and GNFT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $35.00
5/13/2025
Cellectis S.A. stock logo
CLLS
Cellectis
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$5.00 ➝ $4.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$55.00 ➝ $48.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$54.00 ➝ $44.00
5/6/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
4/10/2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$58.00 ➝ $45.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cellectis S.A. stock logo
CLLS
Cellectis
$49.22M1.83N/AN/A$2.36 per share0.69
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$67.00M2.77$0.07 per share52.61$1.50 per share2.47
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$34.51M19.49N/AN/A$0.87 per share9.62
NantKwest, Inc. stock logo
NK
NantKwest
$40K7,626.81N/AN/A$1.23 per share2.27
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$347.68M6.74N/AN/A$8.07 per share4.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cellectis S.A. stock logo
CLLS
Cellectis
-$36.76M-$0.86N/AN/AN/A-114.82%-62.55%-21.19%8/5/2025 (Estimated)
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
$1.63MN/A0.00N/AN/AN/AN/AN/A7/24/2025 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.32N/A22.03N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)
NantKwest, Inc. stock logo
NK
NantKwest
-$65.79M-$0.70N/AN/AN/A-76,658.58%-56.06%-46.93%N/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$208.73M-$3.25N/AN/AN/A-54.98%-33.48%-25.34%8/1/2025 (Estimated)

Latest MGTX, CLLS, TWST, NK, and GNFT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025N/A
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.15N/AN/AN/A$10.07 millionN/A
8/1/2025Q3 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.54N/AN/AN/A$95.52 millionN/A
5/13/2025Q1 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
5/12/2025Q1 2025
Cellectis S.A. stock logo
CLLS
Cellectis
-$0.1540-$0.18-$0.0260-$0.18$12.71 million$12.03 million
5/5/2025Q2 2025
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.56-$0.66-$0.10-$0.66$92.00 million$92.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cellectis S.A. stock logo
CLLS
Cellectis
N/AN/AN/AN/AN/A
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
N/AN/AN/AN/AN/A
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
NantKwest, Inc. stock logo
NK
NantKwest
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cellectis S.A. stock logo
CLLS
Cellectis
0.44
1.67
1.67
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
0.08
1.23
1.23
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.34
1.53
1.51
NantKwest, Inc. stock logo
NK
NantKwest
N/A
4.74
4.74
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
4.51
4.24

Institutional Ownership

CompanyInstitutional Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
63.90%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
2.24%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
NantKwest, Inc. stock logo
NK
NantKwest
9.38%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Cellectis S.A. stock logo
CLLS
Cellectis
16.41%
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
4.20%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
NantKwest, Inc. stock logo
NK
NantKwest
71.73%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cellectis S.A. stock logo
CLLS
Cellectis
29055.58 million46.46 millionOptionable
GENFIT S.A. Unsponsored ADR stock logo
GNFT
GENFIT
12050.00 million47.90 millionNot Optionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.37 million74.34 millionOptionable
NantKwest, Inc. stock logo
NK
NantKwest
160109.35 millionN/ANot Optionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99059.92 million58.11 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Cellectis stock logo

Cellectis NASDAQ:CLLS

$1.62 +0.02 (+0.93%)
Closing price 07/9/2025 03:56 PM Eastern
Extended Trading
$1.56 -0.06 (-3.94%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

GENFIT stock logo

GENFIT NASDAQ:GNFT

$3.71 +0.03 (+0.71%)
As of 07/9/2025 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$8.37 +0.30 (+3.72%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$8.36 -0.01 (-0.07%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

NantKwest stock logo

NantKwest NASDAQ:NK

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$39.12 +2.14 (+5.79%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$39.34 +0.22 (+0.56%)
As of 04:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.